United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application

Author's Avatar
Oct 18, 2021

Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning

Complete response cites an open inspection issue at a third-party analytical testing facility; no other deficiencies cited

Approval and launch expected in summer 2022 or earlier

PR Newswire